2-[(4-甲酰基苯氧基)甲基]苯甲酸甲酯 | 1046494-85-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-[(4-甲酰基苯氧基)甲基]苯甲酸甲酯
• 中文别名: 2-[(4-甲酰基苯氧基)甲基]-苯甲酸甲酯
• 英文名称: methyl 2-((4-formylphenoxy)methyl)benzoate
• 英文别名: Methyl 2-[(4-formylphenoxy)methyl]benzoate
• CAS: 1046494-85-2
• 化学式: C₁₆H₁₄O₄
• 分子量: 270.285
• InChiKey: WOGLGBDQJRVZGD-UHFFFAOYSA-N

物化性质

• 密度：
  1.208

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  2-[(4-甲酰基苯氧基)甲基]苯甲酸甲酯 在 吡啶 、 草酰氯 、 N,N-二甲基甲酰胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 48.75h， 生成 4-amino-6-[[2-(4-formylphenoxymethyl)benzoyl]amino]-2-methylquinoline
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of bivalent antagonists of the nociceptin opioid receptor

  摘要：

  Bivalent ligands constituted by two identical pharmacophores structurally related to the Nociceptin Opioid Receptor (NOPr) antagonist JTC-801 were synthesized and their binding affinities for NOPr were evaluated. The novel ligands are formed by two modified JTC-801 units linked by di-iminic and di-aminic spacers with length ranging from three to ten methylene units. Moreover, the synthesis and the pharmacological characterization were extended to the corresponding univalent ligands. The latter compounds consisted in a single modified JTC-801 unit and an alkyl or alkylamino or alkylimino tail. The purpose of this study is to feature the location and surroundings of the allosteric binding site(s) of pharmacophores containing the 4-aminoquinoline structure. Most important, the bivalent ligands were exploited to reveal the eventual occurrence of a supramolecular receptorial architecture of the NOPr.All the bivalent derivatives 4 and 5 proved to be active in the nanomolar range with no outstanding dependence on the chain length. They showed potencies from three to ten times higher than the corresponding monomers. Consequently, results clearly indicated a positive role of the second pharmacophore in the ligand-protein interaction. The pharmacological profile of I he monomers 7 and 8 clarified the contribution of the linker chain to NOP receptor affinity and suggested the presence of a lipophilic acidic site neighbouring the binding site of the JTC-like ligands.Selectivity of saturated compounds 5, 7, and 8 was tested by binding experiments on delta, kappa and mu opioid receptors. Results indicated a general loss of selectivity as compared to JTC-801. In the [(35)S]GTP gamma S binding assay, all the compounds revealed antagonistic properties at the NOP Receptor.In conclusion the present study set the basis for a systematic investigation on the structural modifications that can be introduced into novel ligands for NOPr and helped to feature the surrounds of the allosteric site of NOPr. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.01.040
• 作为产物：
  描述：

  2-溴甲基苯甲酸甲酯 、 对羟基苯甲醛 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以62%的产率得到2-[(4-甲酰基苯氧基)甲基]苯甲酸甲酯
  参考文献：
  名称：

  Discovery of Novel Boron-Containing N-Substituted Oseltamivir Derivatives as Anti-Influenza A Virus Agents for Overcoming N1-H274Y Oseltamivir-Resistant

  摘要：

  为了解决流感病毒神经氨酸酶抑制剂（NAIs）的耐药性问题，设计并合成了一系列新型含硼N-取代奥司他韦衍生物，以针对神经氨酸酶（NA）的150-腔。在NA抑制实验中发现，大多数新化合物对野生型NA表现出中等的抑制效力。其中，带有4-（3-硼酸苄氧基）苯基基团的2c化合物在对组1 NA（H1N1，H5N1，H5N8和H5N1-H274Y）的抑制活性方面显示出比奥司他韦羧酸盐（OSC）更弱或略有改善。令人鼓舞的是，2c对H5N1-H274Y NA的活性比OSC高出4.6倍。此外，2c对H1N1，H5N1和H5N8的抗病毒活性相当或更强于OSC。此外，2c在体外表现出低细胞毒性，在小鼠1000 mg / kg的剂量下没有急性毒性。采用2c的分子对接来解释其改善的抗H274Y NA活性的可能原因，这可能是由于与周围氨基酸残基（如Arg152，Gln136和Val149）形成关键的额外氢键。综上所述，2c似乎是进一步优化的有前途的先导化合物。

  DOI：

  10.3390/molecules27196426

文献信息

• Dibenzoxepinone Hydroxylamines and Hydroxamic Acids:  Dual Inhibitors of Cyclooxygenase and 5-Lipoxygenase with Potent Topical Antiinflammatory Activity
  作者：R. Richard L. Hamer、John J. Tegeler、Ellen S. Kurtz、Richard C. Allen、Steven C. Bailey、Mary Ellen Elliott、Luther Hellyer、Grover C. Helsley、Penelope Przekop、Brian S. Freed、John White、Lawrence L. Martin

  DOI：10.1021/jm950563z

  日期：1996.1.1

  Hydroxylamine and hydroxamic acid derivatives of a known nonsteroidal antiinflammatory dibenzoxepine series display both cyclooxygenase (CO) and 5-lipoxygenase (5-LO) inhibitory properties. Many of these new dual CO/5-LO inhibitors also exhibit potent topical antiinflammatory activity in the arachidonic acid-induced murine ear edema model. On the basis of their promising profile of in vitro and in

  已知的非甾体类抗炎性二苯并xepine系列的羟胺和羟肟酸衍生物同时显示出环氧合酶（CO）和5-脂氧合酶（5-LO）的抑制特性。这些新的双重CO / 5-LO抑制剂中的许多在花生四烯酸诱导的鼠耳水肿模型中也表现出有效的局部抗炎活性。根据其在体内和体外活性的良好前景，异羟肟酸24h，3-（6,11-dihydro-11-oxodibenz [b，e] oxepin-2-yl）-N-hydroxy-N- +选择+ +甲基丙酰胺（HP 977）和25，3-（6,11-二氢二苯并[b，e]氧杂环丁-2-基）-N-羟基-N-甲基丙酰胺（P10294）作为局部用药的发展候选药物治疗炎症性皮肤病。
• Doxepin analogs and methods of use thereof
  申请人：Edgar M. Dale

  公开号：US20050143348A1

  公开（公告）日：2005-06-30

  The invention relates to novel antihistamines and methods of modulating sleep by administering a doxepin analog or a pharmaceutically effective salt thereof.

  这项发明涉及新型抗组胺药物和通过给予多塞平类似物或其药效盐来调节睡眠的方法。
• US7189757B2
  申请人：——

  公开号：US7189757B2

  公开（公告）日：2007-03-13
• US7326721B2
  申请人：——

  公开号：US7326721B2

  公开（公告）日：2008-02-05
• US7317026B2
  申请人：——

  公开号：US7317026B2

  公开（公告）日：2008-01-08